Some researchers propose that GSDME may be a promising biomarker for cancer detection, for predicting the 5-year patient survival rate 83, and for use in GSDME-mediated PCD initiated immunogenic cell death (ICD) in GSDME-overexpressing cells 54. This evidence concerns the gene GSDME and cancer.